Proteomics Market Report Scope & Overview:

The Proteomics Market size was valued at USD 39.84 billion in 2025 and is expected to reach USD 148.72 billion by 2035, growing at a CAGR of 14.08% over the forecast period of 2026-2035. 

The global proteomics market trend is a growing demand for advanced protein analysis solutions such as mass spectrometry platforms, next-generation sequencing technologies, and protein fractionation systems. The growth of the market is driven by increasing investment in drug discovery research, government funding for life sciences innovation, and rising demand for clinical diagnostics and biomarker identification. This trend is also driven by a growing adoption of precision medicine approaches and the growing focus on protein-based therapeutic development as pharmaceutical companies and academic research institutions become more focused on understanding protein structure and function and are more willing to invest in high-throughput proteomics workflows, resulting in growth in the domestic and international market for reagents, consumables, instruments, and proteomics services across both developed and emerging economies.

For instance, in March 2024, growing investment in life sciences research and improved proteomics infrastructure drove a 19% increase in mass spectrometry platform deployments across academic and pharmaceutical research institutions in North America, boosting protein biomarker discovery and clinical diagnostics adoption.

 Proteomics Market Size and Forecast:

• Market Size in 2025: USD 39.84 billion

• Market Size by 2035: USD 148.72 billion

• CAGR: 14.08% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Proteomics Market - Request Free Sample Report

Proteomics Market Trends

• Proteomics instruments and reagents are being adopted because pharmaceutical companies and academic researchers demand faster protein identification, high-throughput biomarker screening, and quantitative protein expression profiling.

• Customized proteomics workflows based on disease-specific protein panels, sample types, and research objectives to improve drug target identification and clinical diagnostics accuracy.

• The development of AI-integrated mass spectrometry software, cloud-based bioinformatics platforms, and automated protein fractionation systems to improve data interpretation and reduce time-to-discovery in research pipelines.

• Surface plasmon resonance systems, X-ray crystallography tools, and chromatography platforms are all available to ensure accurate protein interaction analysis and structural characterization across drug discovery and clinical research workflows.

• Increased demand for single-cell proteomics, spatial proteomics, and multi-omics integration approaches to enable deeper biological understanding and precision medicine application development.

• Collaboration between instrument manufacturers, reagent suppliers, and contract research organizations to develop integrated proteomics service offerings and improve standardization across clinical and research-grade workflows.

• NIH, EMA, and FDA promoting standards for biomarker validation, proteomics data reproducibility, Good Laboratory Practice (GLP) compliance, and protein-based companion diagnostic development requirements.

The U.S. Proteomics Market was valued at USD 15.54 billion in 2025 and is expected to reach USD 57.64 billion by 2035, growing at a CAGR of 14.05% from 2026-2035. The United States represents the largest market for proteomics, primarily driven by the strong NIH and federal research funding base, high concentration of pharmaceutical and biotechnology companies, and well-developed life sciences infrastructure. Government investments, high levels of academic-industry collaboration, and increased spending on precision medicine and clinical diagnostics technology help to drive growth in the market. Also, the U.S. is the largest regional market in the world, due to the regulatory support and swift adoption of mass spectrometry-based and next-generation proteomics research solutions.

Proteomics Market Growth Drivers:

• Rising Investment in Drug Discovery and Precision Medicine is Driving the Proteomics Market Growth

Rising investment in drug discovery and precision medicine takes the center stage as a growth driver for the proteomics market share, and is driven by the increasing use of protein biomarker identification in early disease detection, the growing pipeline of protein-targeted therapeutics, and pharmaceutical industry demand for high-throughput proteomics workflows that reduce drug development timelines and improve clinical trial outcomes. These investments for proteomics-driven drug target validation and companion diagnostic development are expanding the base of the market, the penetration of mass spectrometry and chromatography platforms, and adding to the overall market share globally.

For instance, in May 2024, proteomics-driven biomarker discovery tools accounted for ~64% of the total analytical instrument investments made by top-20 U.S. pharmaceutical companies, reflecting growing institutional preference and expanding market share for advanced proteomics platforms.

Proteomics Market Restraints:

• High Instrument Costs and Data Complexity Challenges are Hampering the Proteomics Market Growth

High instrument costs and data complexity challenges of proteomics platforms also restrict the proteomics market growth, as a large number of research institutions and clinical laboratories that have access to proteomics technologies remain constrained by capital expenditure limitations or face difficulties processing and interpreting large-scale proteomics datasets without dedicated bioinformatics expertise. This might lead to underutilization of advanced instruments, limited clinical translation of research findings, and reduced return on investment for smaller academic and hospital-based laboratories. As a result, broader adoption suffers and market growth is stunted in regions where research funding is limited and proteomics infrastructure remains underdeveloped.

Proteomics Market Opportunities:

• Expansion of Clinical Diagnostics and Multi-Omics Integration Drive Future Growth Opportunities for the Proteomics Market

The opportunity in clinical diagnostics expansion and multi-omics integration in the proteomics market is in the form of protein-based companion diagnostics, liquid biopsy platforms, and integrated genomics-proteomics disease profiling tools. These solutions provide for early cancer detection, individualized therapy selection based on protein expression patterns, and real-time monitoring of treatment response. Through enhanced clinical utility, regulatory-grade biomarker validation, and operational scalability across hospital and reference laboratory settings, particularly in areas with high oncology and chronic disease diagnostic needs, these technologies may improve patient outcomes, reduce diagnostic delays, and expand the market.

For instance, in April 2024, the FDA reported that protein biomarker-based companion diagnostics submissions increased by 31% year-over-year, highlighting rising clinical demand and increasing regulatory acceptance for proteomics-driven diagnostic tools and expanding the addressable market for proteomics platform providers.

Proteomics Market Segment Analysis

• By product & services, reagents & consumables held the largest share of around 48.36% in 2025E, and the services segment is expected to register the highest growth with a CAGR of 15.22%.

• By application, drug discovery accounted for the leading share of nearly 54.18% in 2025E, and the clinical diagnostics segment is expected to register the highest growth with a CAGR of 15.47%.

• By technology, spectrometry dominated the market with approximately 32.74% share in 2025E, while next-generation sequencing is expected to register the highest growth with a CAGR of 16.18%.

By Application, Drug Discovery Leads the Market, While Clinical Diagnostics Registers Fastest Growth

The drug discovery segment accounted for the largest application share of approximately 54.18% in 2025, owing to heavy pharmaceutical industry reliance on proteomics platforms for target identification, lead compound validation, mechanism-of-action studies, and protein-protein interaction mapping that are central to modern drug development pipelines. Reasons driving the drug discovery segment include increasing biologics and antibody drug pipelines, growing investment in oncology and rare disease therapeutics, and the expanding use of structural proteomics tools such as X-ray crystallography and surface plasmon resonance systems for drug candidate optimization. In addition, the clinical diagnostics segment is slated to grow at the fastest rate with a CAGR of around 15.47% throughout the forecast period of 2026–2035, as hospitals, reference laboratories, and in vitro diagnostics companies seek protein biomarker panels, liquid biopsy proteomics tools, and multiplexed clinical assays for disease staging, treatment monitoring, and early detection. Increased focus on companion diagnostics and personalized medicine contribute to their adoption, while improved regulatory pathways for protein-based diagnostic clearance drive continued investment.

By Product & Services, Reagents & Consumables Lead the Market, While Services Registers Fastest Growth

The reagents & consumables segment accounted for the highest revenue share of approximately 48.36% in 2025, owing to the recurring consumption nature of proteomics reagents across sample preparation, protein digestion, labeling, and detection workflows, as well as strong demand from high-throughput pharmaceutical and academic research environments. Emerging trends, including increasing adoption of pre-optimized proteomics kits and single-use consumable formats for clinical-grade sample processing. In comparison, the services segment is anticipated to achieve the highest CAGR of nearly 15.22% during the 2026–2035 period, driven by the increasing demand from smaller biotech firms and clinical research organizations that prefer outsourced proteomics capabilities over direct capital investment in instrumentation. Drivers include rising adoption of contract proteomics services among life science companies, the preference for specialized protein analysis expertise, and growing demand for integrated bioinformatics and data reporting services. The instruments segment remains a significant revenue contributor as academic institutions, government research laboratories, and pharmaceutical R&D centers continue investing in mass spectrometers, chromatography systems, and electrophoresis platforms to build internal proteomics capabilities.

By Technology, Spectrometry Dominates, while Next-Generation Sequencing Registers Rapid Growth

By 2025, the spectrometry segment contributed the largest revenue share of 32.74% due to the widespread adoption of mass spectrometry as the gold-standard technology for protein identification, quantification, and post-translational modification analysis across pharmaceutical, clinical, and academic research settings. Growing integration of high-resolution tandem mass spectrometry with liquid chromatography systems and the development of data-independent acquisition methods are further consolidating spectrometry's market leadership. The next-generation sequencing segment is projected to grow at the highest CAGR of about 16.18% between 2026 and 2035 due to the growing convergence of genomics and proteomics in multi-omics research workflows and the increasing use of sequencing-based protein expression profiling in precision medicine and clinical genomics programs. Some of the reasons include improved sequencing throughput, declining per-sample costs, better compatibility with single-cell proteomics applications, and growing preference for integrated omics platforms among research institutions and life science companies.

Proteomics Market Regional Highlights:

North America Proteomics Market Insights:

North America held the largest revenue share of over 41.28% in 2025 of the proteomics market due to an established life sciences ecosystem, strong NIH and federal research funding, and high concentration of pharmaceutical, biotechnology, and instrument manufacturer headquarters driving continuous innovation and commercialization. Drivers include widespread adoption of mass spectrometry and chromatography platforms, an improved bioinformatics software infrastructure, growing investment in precision oncology diagnostics, and greater acceptance of proteomics-based companion diagnostic approaches stemming from regulatory advances and clinical validation programs. At the same time, various government research grants, FDA biomarker qualification programs, and enormous investments in proteomics technology from academic medical centers and pharmaceutical companies are anchoring proteomics instrument and reagent demand in the market, and ensuring multibillion dollar revenues across the region.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Proteomics Market Insights:

Asia Pacific is the fastest-growing segment in the proteomics market with a CAGR of 15.83%, as the awareness about advanced protein research tools, government life sciences investment programs, and research infrastructure modernization in countries such as China, Japan, South Korea, and India is growing. Factors including rapid expansion of domestic pharmaceutical industries, rising government funding for proteomics and genomics research, and growing uptake of contract research and manufacturing services are stimulating the market growth. National precision medicine initiatives and academic-industry collaboration programs have been instrumental in accelerating proteomics platform adoption, especially in research clusters and university-affiliated hospital networks. Public-private partnerships and government science funding programs also help in advancing proteomics research capabilities and technology transfer. Increase in demand in the Asia Pacific region owing to rising life sciences R&D expenditure and growing affordability and accessibility of mass spectrometry and next-generation sequencing tools.

Europe Proteomics Market Insights:

The proteomics market in Europe is the second-dominating region after North America on account of an increase in the adoption of next-generation sequencing and multi-omics research approaches, robust Horizon Europe funding for life sciences and personalized medicine research, and increasing clinical proteomics adoption across national healthcare systems. Rising implementation of European protein research initiatives, advanced national biobank programs, favorable government funding for proteomics infrastructure projects, and cross-border academic research collaborations are also contributing to the sustained growth of the market in leading European countries.

Latin America (LATAM) and Middle East & Africa (MEA) Proteomics Market Insights:

In Latin America, and Middle East & Africa, the growing life sciences research investment and increase in academic and hospital laboratory capacity with improving research infrastructure support the proteomics market growth. The rising popularity of affordable proteomics service offerings and growing government investment in national biomedical research programs, along with international collaboration with established research institutions, will aid scientific capability development and clinical proteomics adoption. The increasing number of university research centers and improving pharmaceutical manufacturing capabilities in these regions are continuing to encourage market growth.

Proteomics Market Competitive Landscape:

Thermo Fisher Scientific Inc. (est. 1956) is a global leader in analytical instrumentation and life sciences reagents that focuses on integrated proteomics solutions spanning mass spectrometry, chromatography, and protein analysis consumables for pharmaceutical, clinical, and academic research markets. It uses its comprehensive Orbitrap mass spectrometry platform and broad reagent portfolio to deliver high-throughput proteomics workflows with seamless bioinformatics integration.

• In February 2025, it expanded its proteomics portfolio with the launch of next-generation Orbitrap Astral mass spectrometry capabilities for single-cell proteomics and ultra-high-throughput clinical biomarker discovery, aimed at improving proteome coverage and expanding adoption among pharmaceutical research and clinical diagnostics customers.

Waters Corporation (est. 1958) is a well-known analytical instrument company focused on liquid chromatography, mass spectrometry, and software solutions for pharmaceutical, clinical, and food safety proteomics applications. It invests in integrated LC-MS proteomics platforms and cloud-based data management tools with the hopes of revolutionizing protein characterization workflows with faster, more reproducible, and scalable analytical solutions.

• In June 2024, launched an enhanced SELECT SERIES MRT mass spectrometry platform with advanced protein identification and quantification capabilities for biopharmaceutical characterization and clinical proteomics research applications, expanding adoption across North American and European pharmaceutical development laboratories.

Bruker Corporation (est. 1960) is a leading analytical instrumentation provider in the fields of mass spectrometry, X-ray crystallography, and NMR spectroscopy-based proteomics research. The company's proteomics instrument portfolio focuses on high-resolution structural and functional protein analysis, and features a strong commitment to scientific innovation and continuous performance improvement to complement a strong market presence in both pharmaceutical and academic research settings.

• In September 2024, introduced advanced timsTOF Ultra mass spectrometry and spatial proteomics capabilities within its proteomics platform, strengthening single-cell and tissue-level protein analysis performance and expanding adoption among leading life sciences research institutions and pharmaceutical R&D organizations.

Proteomics Market Key Players:

• Thermo Fisher Scientific Inc.

• Waters Corporation

• Bruker Corporation

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• Merck KGaA

• Shimadzu Corporation

• SCIEX

• Becton, Dickinson and Company

• Illumina, Inc.

• Qiagen N.V.

• Abcam plc

• Cell Signaling Technology, Inc.

• Biognosys AG

• Olink Proteomics

• SomaLogic, Inc.

• Proteome Sciences plc

• Creative Proteomics

• 2seventy bio

• Sartorius AG